heart drugs

AstraZeneca's Brilinta Fails to Win FDA Approval

AstraZeneca failed to win FDA approval for its potential heart drug Brilinta, a drug the company -- which is about to face a severe patent cliff -- had high hopes for. Shares in the U.K. drugmaker dropped in London and were over 5% lower in premarket trading in New York.

AstraZeneca's Heart Drug Brilinta: The FDA Is Ready to Rule

More than a year after AstraZeneca filed for approval of its heart drug Brilinta, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results.